The North America cell therapy market is expected to record a CAGR of 14.13% during the forecast period, 2022-2030, and is predicted to reach a revenue of $3369.23 million by 2030.

The cell therapy market growth in North America is primarily attributed to the rising investments in clinical therapy trials and the strong regulatory framework. Also, the growing government funding contributes to market growth.

To know more about this report, request a free sample copy

The North America cell therapy market growth evaluation includes the analysis of the United States and Canada. One of the key growth drivers of the United States market is the strong regulatory framework. The FDA continually attempts to improve its guidelines regarding legal practice, approval, development, and promotion of cellular therapies. Also, it is making efforts to supplement innovators in swiftly bringing new and effective therapies to patients.

Besides, the companies are collaborating with regulatory agencies to cater to the regulatory model for stem cell therapies. The US Stem Cell Inc has invested over $100 million in the last two decades in preclinical and clinical trials carried out using its MyoCell product. In addition, the presence of associated entities has contributed to its largest share.

Also, the presence of bodies like the International Society for Cellular Therapy, a global society of industry partners, clinicians, regulators, and technologists seeking to translate cellular therapy into efficient therapies to enhance outcomes, is beneficial to market growth. Moreover, the Center for Biologics Evaluation and Research (CBER) regulates certain devices associated with gene & cell therapies, human gene therapy products, and cellular therapy products. It uses the Federal Food Drug and Cosmetic Act and the Public Health Service Act as enabling statutes.

Furthermore, the presence of prominent players and their strategic developments augment market growth opportunities. For instance, the US-based Catalent Inc acquired MaSTherCell, a cell therapy manufacturing specialist based in Gosselies, Belgium, for $315 million in February 2020. Additionally, it acquired a commercial-scale cell therapy development and manufacturing facility in Princeton, New Jersey, in April 2022.

The North America cell therapy market scope includes cell type, therapy type, therapeutic application, and end-user. The cell type segment includes stem cell and non-stem cell. The stem cell segment is further sub-segmented into bone marrow, blood, umbilical cord-derived stem cell, adipose-derived stem cell, and others.

Bone marrow stem cells can develop into mesodermally derived tissues like cardiac muscle or skeletal muscle. A bone marrow transplant can be used to treat people with serious illnesses like myeloma, lymphoma, and leukemia. This procedure is now referred to as a stem cell transplant.

Furthermore, mesenchymal stem cells have been identified as the principal stem cell types deployed in clinics. Also, these are utilized to treat varied problems like degenerative diseases, immunological disorders, trauma or injury, and congenital abnormalities. Besides, adipose-derived stem cells (ASCs) are mesenchymal stem cells (MSCs) produced from abundant adipose tissues that are adhesive on plastic culture flasks, can differentiate into several cell lineages, and are expandable in vitro.

Some of the eminent companies in the North America cell therapy market include Bristol Myers Squibb Company, JCR Pharmaceuticals Co Ltd, Kolon TissueGene Inc, Anterogen Co Ltd, etc.

Bristol Myers Squibb Company (BMS or ‘the company’) is a global biopharmaceutical company engaged in the distribution, marketing, manufacturing, licensing, development, discovery, and sale of innovative medicines. The company develops medicines in several therapeutic areas, including immunoscience, oncology, and cardiovascular. It has a business presence across Asia, Europe, and the Americas, with headquarters in New York City, the United States.

One of its key products, Yescarta, is the first CAR T-cell therapy for adult patients with refractory or relapsed large B-cell lymphoma (LBCL).

Report Synopsis

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.